Cencora (COR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is COR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

The US antitrust regulator filed a lawsuit on Friday in a New York federal court to block Cencora's $3.5 billion sale of its MWI Animal Health unit to veterinary supplier Covetrus, arguing the deal would raise costs fo…

Ethic Inc. lifted its stake in Cencora, Inc. (NYSE: COR) by 22.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,405 shares of the company'…

BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.…

Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structur…

COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.…

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript…

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

Cencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.…

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two years, Cencora has take…

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 per…

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.…

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September …

Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.…

Cencora to acquire American Oncology Network in $2.4 billion deal…

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led netw…

IFP Advisors Inc raised its holdings in Cencora, Inc. (NYSE: COR) by 227.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,264 shares of …

Frank Rimerman Advisors LLC grew its holdings in Cencora, Inc. (NYSE: COR) by 235.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,336 …

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on …

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executi…

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene The…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

